Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory Other Diseases
This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory autoimmune diseaseas as well as cardiometabolic, infectious, neurologic, ophthalmic and pulmonary diseases as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Tremendous progress in bispecific antibody technologies during the last decade has lead to an explosion of the number of bispecific antibodies in clinical development. This report describes 47 clinical and further 25 pre-IND stage bispecific antibodies in addition to numerous preclinical RD programs. The two specificities provide flexibility in the use as:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of RD projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory autoimmune diseaseas as well as cardiometabolic, infectious, neurologic, ophthalmic and pulmonary diseases as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Tremendous progress in bispecific antibody technologies during the last decade has lead to an explosion of the number of bispecific antibodies in clinical development. This report describes 47 clinical and further 25 pre-IND stage bispecific antibodies in addition to numerous preclinical RD programs. The two specificities provide flexibility in the use as:
- T-Cell or NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- RD Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of RD projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. Bispecific Antibodies for Cancer, Inflammatory Other Diseases
T-Cell Redirecting Bispecific Cancer Antibodies
NK Cell Redirecting Bispecific Cancer Antibodies
Bispecific Immuno-Oncology Antibodies
Bispecific Tumor Antigens Targeted Cancer Antibodies
Bispecific Antibodies for Inflammatory Autoimmune Diseases
Bispecific Antibodies Outside Oncology Inflammation
Antibody Cocktails Oligo- and Polyclonal Antibodies
2. Corporate Bispecific Antibody Pipelines
T-Cell Redirecting Bispecific Cancer Antibodies
NK Cell Redirecting Bispecific Cancer Antibodies
Bispecific Immuno-Oncology Antibodies
Bispecific Tumor Antigens Targeted Cancer Antibodies
Bispecific Antibodies for Inflammatory Autoimmune Diseases
Bispecific Antibodies Outside Oncology Inflammation
Antibody Cocktails Oligo- and Polyclonal Antibodies
2. Corporate Bispecific Antibody Pipelines
